Sandy Wong, MD

Hematologist-oncologist

Dr. Sandy Wong sees patients in the Hematology and Blood and Marrow Transplant Clinic, where she cares for people with MGUS, smoldering myeloma, multiple myeloma and amyloidosis.

Wong has a special interest in amyloidosis patients and her research focuses on that disease. She studies AL amyloidosis patients with renal involvement, as well as those with cytogenetic abnormalities, such as deletion 17p. Wong also is designing a clinical trial for a promising new drug to treat multiple myeloma.

Wong graduated from Brown University with a degree in human biology, earning her medical degree at the University of Massachusetts. She then completed an internal medicine residency followed by a hematology/oncology fellowship at Tufts Medical Center in Boston.

An assistant clinical professor at UCSF, Wong is a member of the American Society of Hematology and the American Society of Clinical Oncology.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Fax: (415) 353-2467

Hours: Monday to Friday, 8 a.m. - 5 p.m

Board Certification

Internal Medicine, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Sandy Wong

Additional Languages

Cantonese
English

Education

University of Massachusetts School of Medicine 2009

Residencies

Tufts Medical Center 2012

Fellowships

Tufts Medical Center 2016

Selected Research and Publications

  1. Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018 Apr 05.
  2. Wong SW, Toskic D, Warner M, Varga C, Moreno-Koehler A, Fein D, Fogaren T, Lee L, Oliver CM, Guthrie SD, Comenzo RL. Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center. Clin Lymphoma Myeloma Leuk. 2017 Nov; 17(11):759-766.
  3. Wong SW, Larivee D, Warner M, Sprague KA, Fogaren T, Comenzo RL. Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy. Bone Marrow Transplant. 2017 06; 52(6):936-937.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.